Manzardo, ChristianLondoño, Maria CCastells, LLuisTestillano, MilagrosLuis Montero, JosePeñafiel, JuditSubirana, MartaMoreno, AnaAguilera, VictoriaLuisa Gonzalez-Dieguez, MariaCalvo-Pulido, JorgeXiol, XavierSalcedo, MagdalenaCuervas-Mons, ValentinManuel Sousa, JoseSuarez, FranciscoSerrano, TrinidadIgnacio Herrero, JoseJimenez, MiguelFernandez, Jose RGimenez, CarlosDel Campo, SantosEsteban-Mur, Juan ICrespo, GonzaloMoreno, Asuncionde la Rosa, GloriaRimola, AntoniMiro, Jose M2023-01-252023-01-252018-08-13Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. Am J Transplant. 2018 Oct;18(10):2513-2522http://hdl.handle.net/10668/12665Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV‐RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon‐free regimens with DAAs for post‐LT recurrence of HCV infection in HIV‐infected individuals were highly effective and well tolerated, with results comparable to those of HCV‐monoinfected patients.enClinical research/practiceInfection and infectious agents-viralHuman immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)Liver transplantationHepatitis CAntiviral agentsCoinfectionDrug therapy, combinationFemaleFollow-up studiesHIVHIV infectionsHepacivirusHepatitis CHumansLiver transplantationMaleMiddle agedPrognosisProspective studiesRecurrenceTransplant recipientsresearch article29963780Restricted AccessAntiviralesCoinfecciónInfecciones por VIHPronósticoQuimioterapia combinadaReceptores de trasplantesRecurrenciaTrasplante de hígadoVIH10.1111/ajt.149961600-6143https://www.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.14996